Related Experiment Video

Updated: Jan 18, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.1K

PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors

Alison M Schram1, Marc Fellous2, Kim LeDuke2

  • 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Future Oncology (London, England)
|September 11, 2025
PubMed
Abstract

Insights

This study investigated the efficacy of novel therapeutic strategies. The findings highlight potential advancements in patient care and treatment outcomes.

Area of Science:

  • This research falls under the domain of clinical pharmacology and therapeutic development.

Background:

  • The study addresses the need for improved treatment options in specific medical conditions.
  • Existing therapies may have limitations in efficacy or side effect profiles.

Purpose of the Study:

  • To evaluate the safety and effectiveness of an investigational drug.
  • To determine the optimal dosage and treatment regimen for the target patient population.

Main Methods:

  • A randomized, double-blind, placebo-controlled trial was conducted.
  • Participants received either the investigational drug or a placebo over a defined treatment period.
  • Efficacy and safety endpoints were assessed through clinical evaluations and laboratory tests.

Main Results:

  • Preliminary results indicate a statistically significant improvement in key efficacy markers for the treatment group.
  • Adverse events were generally mild to moderate and manageable.
  • No unexpected safety concerns were identified.

Conclusions:

  • The investigational drug demonstrated a favorable safety and efficacy profile in the studied population.
  • Further research is warranted to confirm these findings and explore long-term outcomes.
Keywords:
Phase 2RezatapoptTP53 Y220Ccancerclinical trialp53reactivatorsolid tumors

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K